Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The page footer revision/version was updated from v3.5.2 to v3.5.3, indicating a site release/version change rather than an update to the clinical study record details.
    Difference
    0.1%
    Check dated 2026-04-24T06:09:23.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Deleted Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T02:31:53.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed from the page header.
    Difference
    0.1%
    Check dated 2026-03-18T22:41:07.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Revision: v3.4.3; no visible changes to study content.
    Difference
    0.1%
    Check dated 2026-03-11T18:12:29.000Z thumbnail image
  7. Check
    89 days ago
    Change Detected
    Summary
    A new site revision label Revision: v3.4.2 appears and a prior government-funding status notice is removed. These are general site-wide UI updates and do not affect the study details or eligibility criteria.
    Difference
    0.4%
    Check dated 2026-02-11T05:34:37.000Z thumbnail image
  8. Check
    96 days ago
    Change Detected
    Summary
    A system notice about government funding lapse and NIH Clinical Center status was added, and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T05:16:53.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.